Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs), announced a correction to its April 28, 2026 press release regarding its partnership with TARA Mind. The correction removes references to Veterans Exploring Treatment Solutions from earlier paragraphs, while reaffirming the collaboration's alignment with a recent executive order aimed at advancing mental health treatments and clinical research participation.
The partnership with TARA Mind is designed to support Phase 3 recruitment for Helus Pharma's HLP003 program, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder. HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. The collaboration also seeks to expand outreach in veteran communities, a key demographic for mental health interventions.
The correction notes that the partnership remains focused on leveraging TARA Mind's network to accelerate enrollment in clinical trials, particularly among veterans who may benefit from novel treatments for depression and anxiety. This aligns with a recent executive order emphasizing the need for innovative approaches to mental health care and increased clinical trial participation among underserved populations.
Helus Pharma, the commercial operating name of Cybin Inc., founded in 2019, is dedicated to developing synthetic molecules designed to activate serotonin pathways that promote neuroplasticity. The company's NSAs aim to address the large unmet need for individuals suffering from depression, anxiety, and other mental health conditions. Helus Pharma's portfolio includes HLP003 for major depressive disorder and HLP004, a proprietary NSA in Phase 2 for generalized anxiety disorder, along with an extensive research portfolio of investigational NSAs.
The company operates in Canada, the United States, the United Kingdom, and Ireland. For more information, visit www.helus.com or follow the team on X, LinkedIn, YouTube, and Instagram. The full press release is available at https://ibn.fm/re8HL.
This correction highlights the importance of accuracy in communications regarding partnerships and clinical trial recruitment, especially as they relate to vulnerable populations like veterans. The reaffirmation of the partnership's goals underscores Helus Pharma's commitment to advancing mental health treatments through rigorous clinical development and targeted outreach.
